LifeSensors, Inc. Launches their Ubiquitin Pathway Enzymes Assay Kits Licensed from Progenra, Inc.

MALVERN, Pa.--(Business Wire)--
LifeSensors, Inc., a biotechnology company specializing in protein expression
technologies and ubiquitin pathway research tools and protein microarrays,
announced today the launch of their CHOP2 Reporter assay kits for
deubiquitylases (DUBs) and the imminent launch of their ubiquitin ligase assay
kits. These proprietary technologies were developed by and licensed from
Progenra, Inc. (www.progenra.com). The conjugation and deconjugation of
ubiquitin and ubiquitin-like proteins (UBLs) are areas of intense interest
within the academic and pharmaceutical communities due to their central roles in
human heath and disease. It is likely that many pioneering drugs will emerge
from research on ubiquitin and ubiquitin-like protein pathways. The assay
platforms will aid in the identification and further characterization of the
approximately 100 DUBs and 700 ligases in the human genome. Ongoing drug
discovery and development programs by Progenra and others demonstrates the
utility of these assay platforms to identify and characterize novel modulators
of DUBs and ligases.

Among the key benefits of the CHOP Reporter Assay Kits include sensitive, rapid,
and robust, fluorescent readouts of enzymatic activity within 30 mins with
minimal interference from screening compounds. Currently, two CHOP reporter
enzymes are available (CHOP1 and CHOP2) enabling multiplexing. The CHOP reporter
platform is superior to traditional off-the-shelf assay technologies and will
play a major role in drug discovery and diagnostics.

According to Jeffrey Boily, LifeSensors` Chief Operating Officer, "The new CHOP2
assay kit further demonstrates LifeSensors` leadership in SUMO and Ubiquitin
tools and Technologies, enabling our customers to achieve breakthroughs in
research and in therapeutic and diagnostic markets."

Michael Mattern PhD, Vice President Research and COO of Progenra commented, "We
have successfully used the CHOP reporters and the E3 ligase assay platforms to
identify novel small molecule inhibitors of numerous DUBs and ligases and are
happy to license our proprietary assay technologies to LifeSensors, Inc., a
proven leader in the commercialization of ubiquitin pathway tools and reagents."

About LifeSensors, Inc.

LifeSensors, Inc. is a biotechnology company that discovers, develops,
manufactures, and markets protein expression technologies. Its customers are
pharmaceutical and biotechnology companies worldwide as well as academic and
government institutions. For more information on the new line of products,
please refer to the web site at www.lifesensors.com.

About Progenra, Inc.

Progenra, Inc. is a world leader in ubiquitin pathway and drug discovery
research. Its mission is to discover and develop pioneering medicines for unmet
medical needs. The company is committed to wider application of its licensed
technology for academia and industry.

LifeSensors, Inc., Malvern, PA
Jeff Boily
Phone: 610-644-8845 X 320
Fax: 610-644-8616
www.lifesensors.com
or
Progenra, Inc., Malvern, PA
Michael Mattern
Phone: 610-644-6974 X 319
Fax: 610-644-4705
www.progenra.com

Copyright Business Wire 2009